Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”


HHS - 850 - National Institute on Drug Abuse Special Emphasis Panel - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Institute on Drug Abuse Special Emphasis PanelAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number850
Original Establishment Date10/27/1986Committee StatusChartered
Actual Termination Date Committee URLhttp://www.drugabuse.gov/about-nida/advisory-bo...
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*Unlimited
Current Charter Date8/7/1995Designated Fed Officer Position Title*CHIEF, SCIENTIFIC REVIEW BRANCH
Date Of Renewal Charter Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*DHARMENDAR
Exempt From Renewal*YesDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*RATHORE
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPHD
Specific Establishment Authority*42 U.S.C. 282(b)(16)Designated Federal Officer Phone*(301) 402-6965
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*301-443-0538
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*dharmendar.rathore@nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Special Emphasis Panel
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*This committee is composed of recognized biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications in the field relevant to drug abuse in the areas of biomedical, basic and clinical neuroscience, basic behavioral science, treatment, health services, epidemiology, prevention, human development, and AIDS. During this reporting period the committee reviewed 958 applications requesting $1,591,761,287 and reviewed 12 contract proposals.
How is membership balanced?*Operation of the Special Emphasis Panel is accomplished using a fluid membership, with members designated to serve for individual meetings rather than formally appointed for fixed terms of service. The reviewers for each meeting are selected to evaluate grant applications or contract proposals for a specific, perhaps narrow, expertise area. Participants for each meeting are assembled to most efficiently and effectively cover the number and breadth of applications or contracts requiring review. The members designated to this committee are authorities knowledgeable in the fields of biomedical, basic and clinical neuroscience, basic behavioral science, treatment, health services, epidemiology, prevention, human development, and AIDS.
How frequent & relevant are cmte mtgs?*The committee held 63 meetings during this reporting period.
Why advice can't be obtained elsewhere?*This committee is composed of recognized biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications and contract proposals. These evaluations and recommendations cannot be obtained from other sources because the specialized, complex nature of the applications and proposals requires a unique balance and breadth of expertise not available on the NIH staff or from other established sources.
Why close or partially close meetings?The meetings of the committee were closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permits the closing of meetings where discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation RemarksThis committee did not produce any reports this reporting period.

The DFO and Committee Decision Maker positions are held by the same individual based on assigned duties within the IC.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingYesAction Approved Grants Or Other PaymentsYes
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentAn action of approved or recommended for grants receiving initial peer review by this committee does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by a National Advisory Council for program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps have been completed, NIH officials make funding decisions on individual grant applications.
Outcome Implement Laws/Reg RequirementsNoGrants Review*Yes
Outcome OtherNoNumber Of Grants Reviewed958
Outcome CommentNANumber Of Grants Recommended958
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$1,591,761,287.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases. Also, there are no comparable alternative mechanisms to determine cost savings accrued using the current committee structure.Grants Review CommentThe committees do not make approval/disapproval recommendations; instead they rate the applications on a scale ranging from 100-500.
Number Of Recommendations*12,660Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentNAAccess Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentNIH Peer Review Committees are involved in the initial review of research grant applications. The NIH dual peer review system is mandated by statute in accordance with section 492 of the Public Health Service Act. The charge to this committee is to determine scientific and technical merit of the individual grants or contracts. These recommendations are forwarded to Federal officials who generally accept the committee’s recommendations and favorable applications are then forwarded for the second level of review performed by Institute and Center (IC) National Advisory Councils or Boards. Only applications that are favorably recommended by both the initial peer review committee and the Advisory Council may be recommended for funding.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentNIH Peer Review Committees are involved in the initial review of research grant applications. The NIH dual peer review system is mandated by statute in accordance with section 492 of the Public Health Service Act. The charge to this committee is to determine scientific and technical merit of the individual grants or contracts. These recommendations are forwarded to Federal officials who generally accept the committee’s recommendations and favorable applications are then forwarded for the second level of review performed by Institute and Center (IC) National Advisory Councils or Boards. Only applications that are favorably recommended by both the initial peer review committee and the Advisory Council may be recommended for funding.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Information resulting from closed initial peer review meetings is subject to the Freedom of Information Act. The public can view information on research projects funded by NIH on the RePORT (Research Portfolio Online Reporting Tool) website located at http://report.nih.gov.Narrative Description*The National Institute on Drug Abuse Special Emphasis Panel performs a vital function of determining the quality of scientific proposals. This evaluation serves as the basis for making funding decisions in NIDA. The Committee is meeting its mission by providing high-quality, unbiased, and timely scientific reviews in the area of drug abuse.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$216,200.00Est Payments to Non-Fed Members Next FY*$216,200.00
Payments to Federal Members*$4,055.00Est. Payments to Fed Members Next FY*$4,055.00
Payments to Federal Staff*$2,235,500.00Estimated Payments to Federal Staff*$2,392,808.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$217,568.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$0.00Est. Other Costs Next FY*$67,259.00
Total Costs$2,455,755.00Est. Total Next FY*$2,897,890.00
Date Cost Last Modified9/16/2022 5:27 PMEst. Fed Staff Support Next FY*15.30
Federal Staff Support (FTE)*14.50Est Cost RemarksProjected costs for FY23 were increased in the event that in-person/hybrid meetings resume. The federal staff cost and staff support years differences between FY22 and FY23 are due to continued staffing changes and the realignment of work in support of the NIDA SEPs.
Cost RemarksMeetings were held virtually in FY22 due to the ongoing COVID-19 pandemic. The FY22 Operating Costs are higher than the FY21 costs due to an increase in the number of meetings. The federal staff cost and staff support years differences between FY21 and FY22 are due to staffing changes and the realignment of work in support of the NIDA SEPs. Daily salary costs have been estimated for Federal and/or Ex Officio members of this committee. The dollar figure represents a portion of their annual salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employee due to membership on this committee.  
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Health Care
Medicine
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-040371National Institute on Drug Abuse Special Emphasis Panel2021
 COM-038649National Institute on Drug Abuse Special Emphasis Panel2020
 COM-036520National Institute on Drug Abuse Special Emphasis Panel2019
 COM-034728National Institute on Drug Abuse Special Emphasis Panel2018
 COM-001694National Institute on Drug Abuse Special Emphasis Panel2017
 COM-002239National Institute on Drug Abuse Special Emphasis Panel2016
 COM-004082National Institute on Drug Abuse Special Emphasis Panel2015
 COM-004422National Institute on Drug Abuse Special Emphasis Panel2014
 COM-005921National Institute on Drug Abuse Special Emphasis Panel2013
 COM-006502National Institute on Drug Abuse Special Emphasis Panel2012
 COM-008013National Institute on Drug Abuse Special Emphasis Panel2011
 COM-008739National Institute on Drug Abuse Special Emphasis Panel2010
 COM-010260National Institute on Drug Abuse Special Emphasis Panel2009
 COM-010673National Institute on Drug Abuse Special Emphasis Panel2008
 COM-012226National Institute on Drug Abuse Special Emphasis Panel2007
 COM-012895National Institute on Drug Abuse Special Emphasis Panel2006
 COM-013965National Institute on Drug Abuse Special Emphasis Panel2005
 COM-014793National Institute on Drug Abuse Special Emphasis Panel2004
 COM-015724National Institute on Drug Abuse Special Emphasis Panel2003
 COM-016758National Institute on Drug Abuse Special Emphasis Panel2002
 COM-017829National Institute on Drug Abuse Special Emphasis Panel2001
 COM-018539National Institute on Drug Abuse Special Emphasis Panel2000
 COM-019575National Institute on Drug Abuse Special Emphasis Panel1999
 COM-020352National Institute on Drug Abuse Special Emphasis Panel1998
 COM-021708National Institute on Drug Abuse Special Emphasis Panel1997